Page 21 - முர்டோக் குழந்தைகள் ஆராய்ச்சி நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(ASX:ANP) has announced a new R&D collaboration with researchers at the Murdoch Children’s Research Institute’s (MCRI) to further investigate the potential of its ATL1102. The researchers, Dr Peter Houweling and Associate Professor Shireen Lamande, will investigate the potential of ATL1102 to deliver treatment for the control of immune-mediated inflammatory muscle damage in muscle diseases. The company said ATL1102 has been shown to be clinically active in Multiple Sclerosis and Duchenne muscular dystrophy (DMD) patients while antisense inhibition of CD49d has also previously demonstrated activity in multiple disease animal models. “The MCRI researchers and ANP have additionally undertaken experimental work that showed antisense inhibition of CD49d in the X chromosome-linked muscular dystrophy (mdx) mouse model of DMD reduces both the CD49d target in the muscle and muscle damage. This data is expected to be submitted for publication in 2021,” said the company.

Peter houwelingGeorge tachasShireen lamandeMurdoch children research instituteMurdoch childrenResearch instituteAssociate professor shireen lamandeMultiple sclerosisAntisense therapeuticsமுர்டோக் குழந்தைகள் ஆராய்ச்சி நிறுவனம்முர்டோக் குழந்தைகள்ஆராய்ச்சி நிறுவனம்பல ஸ்க்லரோசிஸ்